Bayer’s Kerendia, already FDA approved in one cardiometabolic indication, now has data from a pivotal test that support expanding the drug’s label to heart failure. In preliminary results reported ...
Two Sarepta Therapeutics drugs for treating different genetic subsets of patients with Duchenne muscular dystrophy failed the confirmatory study required of their accelerated FDA approvals. Sarepta ...
Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial, causing the stock to plummet ~90% and trade near book value. The company's decision to discontinue other simufilam trials signals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback